Literature DB >> 10596389

D1/D2 receptor synergism on CREB DNA-binding activities in the caudate-putamen of rat.

K Kashihara1, T Ishihara, K Akiyama, K Abe.   

Abstract

Cyclic AMP-responsive element-binding protein (CREB) is a transcription factor that is activated by cyclic AMP-dependent protein kinase and regulates the induction of fos. In order to elucidate the cellular pathway of D1/D2 dopamine receptor synergism, the effect of D1 and D2 agonists on CREB DNA-binding activities was studied in the caudate-putamen of rats with an ipsilateral 6-hydroxydopamine-lesion of the medial forebrain bundle. Combined administration of D1 (SKF38393) and D2 (bromocriptine or quinpirole) agonists resulted in enhanced CREB-binding activities at a dose that did not enhance it when given separately. These results suggest that D1/D2 dopamine receptors play synergistic role in inducing CREB DNA-binding activities in the dopamine-depleted caudate-putamen of rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10596389     DOI: 10.1080/01616412.1999.11741014

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  3 in total

1.  Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration.

Authors:  Nigel S Bamford; Hui Zhang; John A Joyce; Christine A Scarlis; Whitney Hanan; Nan-Ping Wu; Véronique M André; Rachel Cohen; Carlos Cepeda; Michael S Levine; Erin Harleton; David Sulzer
Journal:  Neuron       Date:  2008-04-10       Impact factor: 17.173

Review 2.  cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia.

Authors:  Haitao Wang; Jiangping Xu; Philip Lazarovici; Remi Quirion; Wenhua Zheng
Journal:  Front Mol Neurosci       Date:  2018-08-30       Impact factor: 5.639

Review 3.  Enkephalin as a Pivotal Player in Neuroadaptations Related to Psychostimulant Addiction.

Authors:  Bethania Mongi-Bragato; María P Avalos; Andrea S Guzmán; Flavia A Bollati; Liliana M Cancela
Journal:  Front Psychiatry       Date:  2018-05-28       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.